Additional file 1 1 of 9

## Survey questionnaire

## Welcome

Elicitation and Recording of Participant-reported Safety Data in Malaria Clinical Drug Trials/Studies

We are interested in talking to malaria clinical research team members about the details of how malaria clinical research participants (or their caregivers, such as a parent) are asked about their health and treatment-taking in order to collect medical history, adverse event and concomitant medication (safety) data. The survey is not about spontaneous reporting of adverse drug reactions (yellow-card, prescription event monitoring etc.) or vaccine clinical research.

This voluntary survey should take about 15-20 minutes. We would like to be able to follow up with you about specific methods you have used and have the opportunity to work with you in future collaborations. We would therefore be grateful if you would provide your name and contact details. These will be stored in secure electronic and paper files and will not be used in any report.

Should other members of your research team have used the same methods to collect safety data then one person may respond on behalf of the team. Ideally, this should be a clinical investigator or someone who has been involved in the selection or development of methods used to collect participant-reported safety data.

1) In which country do you work most of the time? ( ) Abkhazia to ( ) Zimbabwe
2) Your name:
3) What is the name of the organization where you work?
4) Phone number (please include country and area codes!):
5) Email address:
6) How long have you been involved in <i>malaria</i> clinical research?*
( ) Have never been involved in malaria clinical research
( ) < 1 year
( ) 1-5 years
( ) > 5 years
7) Indicate your most recent primary role within malaria clinical research? Check the one that fits your role best.*
( ) Working at an investigational site
( ) Representative of a sponsor (other than sponsor-investigator)
( ) Other:
Indicate your most recent primary role at an investigational site?
( ) Principal investigator
( ) Co-investigator or sub-investigator
( ) Study coordinator

Additional file 1	2 of 9
( ) Research nurse	
( ) Research team member other (briefly describe role):	_
( ) Other:	
8) Is the majority of your malaria clinical research sponsored by:	
( ) Pharmaceutical companies	
() Non-commercial entities (e.g. Medicines for Malaria Venture)	
( ) Your own institution (i.e. a member of the team is a Sponsor-investigator)	
( ) Other:	
9) Have you had responsibility for <i>selecting or developing</i> methods used to medication data in clinical trials/studies?	collect adverse event or concomitant
() Yes	
( ) No	
Please consider your <i>most recent malaria</i> clinical drug research study when as a parent) were asked about their health and use of treatments to collect concomitant medication data.	
10) What type of study was your most recent malaria clinical research stud	ly? Check all that apply:
[] Interventional	
[ ] Observational	
[ ] Single arm	
[] Multiple arms	
[ ] Randomized allocation	
[] Other	
11) What was the research population of your most recent malaria clinical	research study? Check all that apply:
[] Adults	
[] Children <1year	
[ ] Children 1-5 years	
[ ] Children 5-12 years	
[] Children 12-17 years	
[ ] Healthy volunteers	
[ ] Patients with malaria	
[] Other	
In general, from about what age were children asked directly about their h	ealth?
( ) Age in years:	
( ) Children were NOT asked directly at all	
( ) Don't know	

Additional file 1 3 of 9

In general, from about what age were children asked directly about their use of treatments?
( ) Age in years:
( ) Children were NOT asked directly at all
( ) Don't know
12) Which staff members were involved in asking participants (or their caregivers) about their health and use of treatments? Check all that apply:
[] Medical doctor
[ ] Study nurse
[] Other
13) Were questions about health and use of treatments ever asked through a translator?
() Yes
( ) No
( ) Don't know
Asking participants (or their caregivers) about <i>health</i> to collect adverse event (AE) data, at visits <i>after</i> the first visit.
14) Were participants (or their caregiver) asked about their <i>health</i> since baseline using a general question <i>without</i> reference to a particular condition or body system, e.g. 'how have you been feeling?' or 'has your child experienced any problems?'
() Yes
( ) No
( ) Don't know
Please give the phrase(s) or question(s) used:
( ) Don't know
( ) Phrase(s) used:
Did the study require this particular phrase(s) be used for the general question(s)?
() Yes
( ) No
( ) Don't know
How confident are you that all staff used the study-specific phrase(s) most of the time?
( ) Confident
( ) Not confident

Asking participants (or their caregivers) about their *health* to collect adverse event (AE) data, at visits *after* the first visit (continued).

Additional file 1 4 of 9

15) Were participants (or their caregiver) asked about any <i>change in their health</i> since baseline using <i>structured</i> questions, e.g. 'please tell me if you have experienced fever, cough, headache?' or 'has your child had any problems with the chest, head?'
() Yes
( ) No
( ) Don't know
Did the study require particular questions be asked, e.g. using a prepared list of possible options?
() Yes
( ) No
( ) Don't know
How were health issues defined in the questions? Check all that apply:
[] By symptom
[] By body system
[ ] Expected adverse events
[ ] Malaria symptoms
[] Other
How were options presented? Check all that apply:
[] Staff used the exact words as prepared
[ ] Staff rephrased items in their own words
[] Items were only presented if they had been reported at a previous visit
[] Other
Please describe any non study-specific structured questions asked:
( ) Question(s) used:
( ) Don't know
16) Were participants (or their caregiver) asked about their <i>health</i> since baseline in <i>another way</i> to the general or structured method (e.g. picture tool, diary)?
() Yes
( ) No
( ) Don't know
Please briefly describe the method(s):
17) What was the rationale for using the above whole approach to questioning about <i>health</i> in this study?

18) Was this same approach to questioning participants (or their caregivers) about their health to collect AEs,

also used when asking about medical history at baseline?

Additional file 1	5 of 9
() Yes	
( ) No	
( ) Don't know	
19) How was the questioning about health different at baseline?	
20) Does the above approach to questioning participants (or their caregivers malaria clinical studies you have been involved in?	s) about their <i>health</i> reflect <i>most</i>
() Yes	
( ) No	
( ) Don't know	
( ) Other:	
Please briefly describe other questioning methods or combinations of methods	ods used:
21) What do you consider as an <i>optimal</i> (important and feasible) approach f caregivers) about their <i>health</i> to collect AE data:	or asking participants (or their
( ) The approach reported above	
( ) A different approach to my above report (briefly describe):	
22) Why do you consider that optimal?	
Recording of adverse events (AEs) in the database.	
23) How were the participants' (or their caregivers') reports eventually <i>reco</i> lall that apply:	rded in the database as AEs? Check
[ ] As verbatim participant (or caregiver) reports	
[] According to staff members' own terminology for symptom or diagnosis	
[ ] Standard terminology (e.g. specific coding method)	
[] Other	
Which standard terminology or coding system was used?	
24) How did you assess AEs for severity, if at all?	
( ) Not assessed for severity	
( ) Published grading scale	
( ) Other grading scale method	
( ) Don't know	
Please provide us with a reference to the grading scale or a description of th	e method used, if known:
25) How did you assess adverse events for <i>causality</i> , if at all?	
( ) Not assessed for causality	

Additional file 1	6 of 9
( ) Published causality rating	
( ) Other causality rating method	
( ) Don't know	
Please provide us with a reference to the rating scale or a description of th	e method used, if known:
Asking participants (or their caregivers) about their use of treatments (other previous and concomitant medication data.	er than the study drug) to record
26) Were participants (or their caregiver) questioned about their <i>use of no</i> question <i>without</i> reference to a particular treatment class or name, e.g. 'Pl have used' or 'Please tell me about any treatment your child is currently us	lease tell me about any treatment you
() Yes	
( ) No	
( ) Don't know	
Please give the phrase(s) or question(s) used:	
( ) Don't know	
( ) Phrase(s) used:	
Did the study require this particular phrase(s) be used for the general ques	tion(s)?
() Yes	
( ) No	
( ) Don't know	
Which of the following were explicitly referred to during general questioni	ng (check all that apply):
[] Prescription medicines	
[ ] Over the counter medicines	
[ ] Traditional treatments	
[ ] Supplements	
[ ] Vaccinations	
[] Other	
27) Were participants (or their caregiver) questioned about their <i>use of no</i> or <i>structured</i> questions, e.g. 'Have you taken paracetamol, antibiotics?'	n-study treatments by asking specific
() Yes	
( ) No	
( ) Don't know	
Did the study require particular questions be asked, e.g. using a prepared I	ist of possible options?
() Yes	
( ) No	

Additional file 1 8 of 9

Please briefly describe other questioning methods or combinations of methods used:

31) What do you consider as an <i>optimal</i> (important and feasible) approach for asking participants (or caregivers) about their <i>use of non-study treatments</i> to collect previous and concomitant medication data:		
( ) The approach reported above		
( ) A different approach to my above report (briefly describe):		
32) Why do you consider that optimal?		
Please consider your <i>most recent malaria</i> clinical research study where participants (or their caregiver, such as a parent) were asked about adherence to treatment(s) given during the study, when answering the questions on this page.		
33) What was the study drug regimen?		
34) Did you collect individual participant data on drug intake?		
() Yes		
( ) No		
( ) Don't know		
35) What was the reason for not collecting such data?		
( ) Don't know		
( ) Reason(s):		
36) How did you collect the data? Check all that apply:		
[] Dose observed		
[] Participant (or caregiver) recall		
[ ] Pill count (manual/electronic)		
[ ] Dispensing confirmation		
[ ] Pill diary		
[] Other		
Were all drug doses observed?		
( ) All doses observed		
( ) Some doses observed		
( ) Don't know		
37) Which data did you record? Check all that apply:		
[] Quantity of dose dispensed		
[ ] Dose given		
[] Duration of total therapy		
[] Time of dose		

Additional file 1	9 of 9
[] Whether participant vomited	
[] Reason(s) for non-adherence	
[] Whether taken with food/drink	
[] Other	
Was time of dose recorded for all drug doses?	
( ) Time was recorded for all doses	
( ) Time was recorded for some doses	
( ) Don't know	
When it was recorded that a participant vomited, what action was taken	and how was this recorded?
38) How did you define adherence levels in your study?	
39) Did you report adherence in the trial report?	
() Yes	
( ) No	
( ) Don't know	
General	
41) We would appreciate if you would suggest any <i>references</i> that you kndescribe any references you may know of here:	now to be relevant for this work. Please
42) Would you like to hear about future projects for this topic?	
[] Yes	
Thank you for taking the time to complete this survey, we appreciate you	ır input into this complex topic.